Shanghai RAAS Blood Products Co.,Ltd (or Shanghai RAAS for short, stock symbol :002252),being set up by the United States Rare Antibody Antigen Supply,Inc and the Shanghai Blood Products Blood Transfusion Equipment Company in October 1988 ,was the first large sino-foreign joint venture in production of blood products . In March 2007 ,Shanghai RAAS was trasferred to limited company as a whole ,and its registed capital was12,000yuan and Kerui Tiancheng Klc Holdings Ltd and RAAS China Ltd both invested 50% of it. In order to improve the level of medical care and health care in China and other developing countries, Shanghai RAAS research ，invent and develop new products for the treatment of blood diseases to meet the demand of the market for high-quality blood products . Since it was founded 28 years ago, RAAS has been adhering to the quality policy of "safe, high quality, high efficiency" and it has created 11 products , covering three categories of blood products: human blood proteins, human immunoglobulin and blood coagulation factor. Shanghai RAAS will actively integrate global resources by layouting innovation chains around the blood products industry,and building three innovation fulcrums among national think tank , industrial research institute and international laboratory to form the innovation ecosystem in blood products industry . By taking internal growth as the root and taking epitaxial M & A as the cross, RAAS will making every effort to be the "national aircraft carrier enterprise"of the world's blood products industry .